Safety profile of antidepressant for <scp>Japanese</scp> adults with major depressive disorder: A systematic review and network meta‐analysis-Reference-Cited by-同舟云学术

Safety profile of antidepressant for Japanese adults with major depressive disorder: A systematic review and network meta‐analysis

Published:2023-12-10 Issue:2 Volume:78 Page:142-144
ISSN:1323-1316
Container-title:Psychiatry and Clinical Neurosciences
language:en
Short-container-title:Psychiatry Clin Neurosci

Author:

Kishi Taro¹^ORCID,Ikuta Toshikazu²,Sakuma Kenji¹,Hatano Masakazu³^ORCID,Matsuda Yuki⁴^ORCID,Esumi Satoru⁵,Miyake Nobumi⁶,Miura Itaru⁷,Kato Masaki⁸,Iwata Nakao¹

Affiliation:

1. Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan

2. Department of Communication Sciences and Disorders School of Applied Sciences, University of Mississippi University Mississippi USA

3. Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine Toyoake Japan

4. Department of Psychiatry Jikei University School of Medicine Tokyo Japan

5. Faculty of Pharmaceutical Sciences Kobe Gakuin University Kobe Japan

6. Department of Neuropsychiatry St. Marianna University School of Medicine Kawasaki Japan

7. Department of Neuropsychiatry Fukushima Medical University School of Medicine Fukushima Japan

8. Department of Neuropsychiatry Kansai Medical University Osaka Japan

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical),Neurology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pcn.13622

Reference10 articles.

1. JSMD.Treatment guideline for major depressive disorder.https://www.secretariat.ne.jp/jsmd/2016.

2. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

3. The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine

4. Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants

5. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure